A Multi-center, One-arm Clinical Trial of Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC
Latest Information Update: 09 Jan 2023
At a glance
- Drugs Catequentinib (Primary) ; Firmonertinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms FOCUS-A
- 05 Jan 2023 Planned primary completion date changed from 30 Nov 2022 to 30 Nov 2023.
- 14 Oct 2021 Status changed from not yet recruiting to recruiting.
- 21 May 2021 New trial record